2025年 中国干细胞行业发展现状及趋 势洞察行业研究报告 2025 China Stem Cell Development Status and Trend Insights Industry Overview 概览标签：干细胞、细胞医疗服务、细胞治疗、细胞存储 报告主要作者：孙榕、姚雪闻 2025/12 1 www.leadleo.com ©2025 LeadLeo 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均 系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外 ）。 ，任何人不得以任何方式擅自复制 、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述 约定的行为发生，头豹研究院保留采取法律措施，追究相关人员责任 的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹 "的商号、商标，头豹研究院无任何前述名称之外的其他分支机构， 也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 www.leadleo.com 研究目的&摘要 研究目的 本报告为2025年中国干细胞行业发展现状 及趋势洞察研究报告，将通过分析产业链 上下游各环节以及各细分行业市场现状， 从 ...

"我一晚没睡，挣的钱都给美容院了。" 两年前，周进发现妻子程璐有笔20万元异常转账，细查之下更感震惊——7年时间，管理家中财务的妻 子竟为所谓"干细胞美容"陆续花费超2000万元。这场始于"高科技护肤"的消费，最终将夫妻二人推上诉 讼之路。今年12月初，二审宣判认定美容院老板存在无资质行医、使用"干细胞"不规范宣传等行为，但 未认定构成欺诈，最终判处退回450余万元。周进决定申请再审，并继续向有关部门举报。 而在个体悲剧背后，一个更广阔的市场乱象正浮出水面：干细胞虽在医学领域展现出修复与分化的潜 力，但近年来，"干细胞美容"俨然成为美容行业的热门标签，从外涂面霜、口服胶囊到直接注射，产品 只要与"干细胞"沾边，便仿佛镀上了一层"神奇"光环。 针对这一乱象，12月5日国家卫生健康委新闻发言人胡强强在新闻发布会上明确强调：干细胞等细胞与 基因治疗必须由具备资质的专业医疗机构开展，美容院、养生馆等非医疗机构不具备资质，不得开展任 何诊疗活动。 随着监管声音的落地与个案诉讼的推进，一场关于干细胞美容虚假宣传与行业规范的公众讨论，正悄然 拉开帷幕。 20万一针"抗衰"还"抗癌"？ 天价账单下的"干细胞美容"幻梦 面对一 ...

诚达药业股份有限公司 | | 大利AIFA、英国MHRA、加拿大HC、希腊等国家药政管理部门的审评， | | --- | --- | | | 并取得了欧洲CEP认证证书，覆盖了全球主流市场的质量体系认证， | | | 产品质量得到了客户的广泛认可。 | | | 4.公司目前的产能情况？ | | | 答：公司募投项目产能逐渐释放，能满足客户不同产品、不同 | | | 阶段、不同规模订单的需求。 | | | 5.公司其他主营业务情况？ | | | 答：公司主营业务涵盖为跨国制药企业及医药研发机构提供关 | | | 键医药中间体、原料药CDMO研发生产服务，左旋肉碱系列产品、原 | | | 料药的研发、生产和销售以及干细胞药物的研发。公司持续聚焦、 | | | 深耕主营业务，后续公司将继续推进新产品、新工艺的研发和技术 | | | 创新工作，开拓产品深度及广度，并争取更加丰富的客户结构。 | | | 6.干细胞项目的进展情况？ | | | 答：公司细胞治疗"心梗项目"、"脑梗项目"已完成GMP厂房 | | | 及设施设备的设计、安装、调试、确认；完成脐带间充质干细胞的 | | | 原代分离、培养及冻存的技术转移，建 ...

开能健康（300272.SZ）12月24日在投资者互动平台表示，公司对细胞行业的前景持积极态度，并早在 2014年开始已在该领域进行了深入布局，创立了原能细胞科技集团。根据公司公告，干细胞治疗作为细 胞治疗的一个重要分支，近年来得到了国家政策的支持，公司紧跟政策导向，积极布局细胞业务板块。 公司通过收购原能集团部分子公司股权，获得了包括张江核心地段的土地、细胞行业专利授 权、"YT001注射液"临床试验批件等在内的一系列资产和项目，进一步完善了公司在细胞治疗领域的产 业链。 公司在干细胞治疗领域的布局具体包括：1、细胞制剂制备业务：公司依托成熟的干细胞与免疫 细胞制备工艺，承接市场需求，包括药企细胞治疗药物的规模化代工生产、科研机构临床研究用细胞定 制服务等。2、细胞试剂业务：公司掌握了细胞制备工艺全链条的自主技术储备，成功研发出拥有自主 知识产权的细胞制备制剂产品，通过技术输出成为产业链关键供应商。3、细胞技术产品研发业务：公 司自主研发的"YT001注射液"已获批准开展I/IIa期临床试验，未来将通过技术产品上市、技术转让或收 益分成实现商业化；4、宠物保健抗衰领域，利用干细胞疗法、NK细胞、外泌体及NM ...

12月5日，国家卫生健康委员会召开"时令节气与健康"主题新闻发布会，邀请医学、疾控等领域专家，围绕冬季常见健康问题、疾病防控 等公众健康关切展开全面解读。发布会既聚焦流感防控、慢性呼吸系统疾病护理、冬季皮肤问题等高频健康痛点，纠正认知误区并提供 可操作的科学方案，也针对近期备受关注的干细胞治疗乱象发布明确规范与风险警示，明确干细胞治疗必须由正规医疗机构开展、未经 批准项目不可尝试，为公众揭穿医疗骗局，从日常健康防护到医疗风险防范，全方位筑牢暖冬健康"防护网"。 流感活动预计将在12月上中旬达峰 随着大雪节气到来，我国大部分地区气温持续走低，急性呼吸道传染病呈上升趋势，慢性呼吸系统疾病、皮肤病等也进入高发期。发布 会上，专家针对公众常见认知误区，给出了科学应对方案。 流感防控方面，中国疾病预防控制中心病毒病所研究员王大燕澄清了"流感只是重感冒"的错误认知。她介绍，流感由流感病毒引起，严 重时可引发肺炎、心脏损伤等并发症，甚至危及生命。当前全国17个省份处于流感高流行水平，预计全国将在12月上中旬达峰的可能性 较大，其中，甲型H3N2亚型流感病毒占比超过95%。 王大燕建议，老年人、慢性病患者、儿童、孕妇等应减少 ...

本报记者 张敏 许林艳 近年来，"干细胞"凭借自我更新与多向分化的核心潜能，已成为全球医学领域的研究热点。今年1月份，我国首款干细胞 治疗药品艾米迈托赛注射液上市。这标志着我国干细胞药物进入商业化阶段。 "2025年可以被定义为干细胞转化应用的元年，因为在这一年，我国首款干细胞新药上市，海南博鳌乐城干细胞收费治 疗，多地密集出台细胞与基因治疗推进政策，国家监管步入统一全流程监管阶段。"云南省细胞治疗技术转化医学重点实验室 主任、云南省成体干细胞治疗技术创新团队带头人潘兴华向《证券日报》记者表示。 清华大学生物医学工程学院长聘教授、副院长杜亚楠预测，未来几年，干细胞治疗的临床试验规模将继续扩大，相关新药 上市数量将增多，适应症范围也将不断拓展。 干细胞治疗何以发展壮大 传统药物大多旨在缓解症状或控制病情发展，而干细胞治疗的目标是修复、替换或再生受损的细胞、组织和器官，试图从 根源上解决疾病问题。它的应用领域涵盖了多个现代医学的难题，比如阿尔茨海默病、疾病或衰老造成的组织损伤等。 "最近30年来，干细胞治疗技术取得了诸多突破性进展，特别是诺贝尔奖级别的成果助推了干细胞治疗技术的发展，其中 核移植、人类胚胎干细胞建 ...

Group 1: Stem Cell Projects - The company is developing stem cell projects for treating heart failure after myocardial infarction and sequelae after cerebral infarction, such as paralysis and speech disorders [2][3] - The stem cells used are mesenchymal stem cells sourced from umbilical cords, which have good in vitro expansion capabilities and maintain their tri-lineage differentiation potential [2][3] - The company has established a technical collaboration with Chiron Pharma, Inc. for the implementation of these projects in mainland China, Hong Kong, and Macau [2][3] Group 2: Project Progress and Infrastructure - The company has completed the design, installation, and validation of GMP facilities for the stem cell projects, including the establishment of seed, master, and working cell banks [3] - The company is preparing for IND submission by completing process validation and developing analytical methods [3] Group 3: Future Business Directions - A wholly-owned subsidiary, Shanghai Jiuqian Cheng Biomedical Co., Ltd., has been established to advance stem cell projects, with future business directions to be determined based on market demand [3] - In addition to stem cell projects, the company continues to focus on its core business of providing key pharmaceutical intermediates and CDMO services, with a recent investment of 70 million yuan in Chengdu Shibeikang Biomedical Technology Co., Ltd. for innovative drug collaboration [3] Group 4: Business Operations - The company's CDMO services include small molecule drug intermediates, small nucleic acid drug intermediates, and raw materials for innovative drugs [3] - The company is committed to disclosing any significant information in accordance with regulations [3]

Core Viewpoint - The company is actively engaging in strategic collaborations to address clinical needs in chronic diseases such as hypertension, diabetes, hyperlipidemia, and arthritis, with a focus on stem cell therapy development [2]. Group 1: Strategic Collaborations - The company has formed a strategic partnership with Hangzhou Ruipu Chenchuang Technology Co., Ltd. to develop stem cell therapy [2]. - The collaboration will focus on the technology of inducing differentiation of pluripotent stem cells into pancreatic islet cells [2]. Group 2: Clinical Research Progress - The RGB-5088 pancreatic islet cell injection for the treatment of type 1 diabetes is currently undergoing clinical research [2]. - The company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [2].

Core Viewpoint - The company is developing a stem cell injection (SC01009) for various diseases, including idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome, with a focus on idiopathic pulmonary fibrosis currently undergoing Phase II clinical trials [1] Group 1 - The company has a stake in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., which is working on the stem cell injection [1] - The indications for the stem cell injection include idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome [1] - The Phase II clinical trial for idiopathic pulmonary fibrosis is currently in progress [1]

Core Points - The 2024 Beijing Science and Technology Awards announced 38 scientists and 193 achievements recognized for their contributions to various fields of science and technology [1] - The awards include categories such as Natural Science Awards, Technological Invention Awards, and Scientific and Technological Progress Awards, with a total of 57, 24, and 112 achievements respectively [1] Group 1: Outstanding Contributions - The Outstanding Contribution Zhongguancun Award was given to Deng Hongkui and Dong Jin for their significant contributions in basic research and key core technology breakthroughs [2][3] - Deng Hongkui developed new methods for cell fate regulation and established a new system for chemical small molecule-induced cell reprogramming, contributing to stem cell therapy advancements [2] - Dong Jin led the development of the "Chang'an Chain," a domestically controllable blockchain technology system, including the world's first 96-core blockchain chip, enhancing China's position in blockchain technology [3] Group 2: Young Scientists - The Outstanding Young Zhongguancun Award recognized 26 young scientists, including Chang Kai, who discovered new two-dimensional ferroelectric and ferromagnetic semiconductor materials [4] - Liu Ying revealed new mechanisms for cellular sensing of amino acids and glucose, providing a theoretical basis for metabolic and aging-related disease treatments [4] - Zhang Linfeng developed deep potential algorithms to address the "curse of dimensionality" in micro-scale simulations, enhancing intelligent scientific research infrastructure [4] Group 3: Basic Research Achievements - Approximately 29.5% of the awarded achievements were in basic research, highlighting significant contributions in fields like new-generation information technology and materials [5] - The "Material Genome Technology Revealing Universal Physical Laws of High-Temperature Superconductors" project won a first-class Natural Science Award, advancing the understanding of superconducting mechanisms [6] - The "New Thin Film Photovoltaic Materials and Devices" project also received a first-class Natural Science Award, leading to advancements in photovoltaic materials and devices [6] Group 4: Breakthroughs in Key Technologies - Major breakthroughs in key technologies were highlighted, including a 100MW advanced compressed air energy storage technology that won a first-class Scientific and Technological Progress Award [7] - The "Lightweight Thin-Walled Structure High-Quality Laser Precision Welding Technology" received a second-class Technological Invention Award, enhancing applications in aerospace and new energy sectors [7] Group 5: Corporate Innovation - Over half of the awarded projects involved enterprises, indicating a strong trend of corporate participation in innovation [8] - The "Advanced Oxide Semiconductor Technology for Intelligent Displays" project won a first-class Scientific and Technological Progress Award, significantly improving display technology and market competitiveness [8] - The "OCT Imaging Equipment for Ophthalmology" project received a second-class Scientific and Technological Progress Award, advancing non-invasive diagnostic capabilities in ophthalmology [8] Group 6: National Strategic Needs - Awarded achievements are aligned with national strategic needs, focusing on areas like renewable energy and aerospace technology [9][10] - The "Electronic High-Capacity DC Voltage Conversion Technology" project won a first-class Technological Invention Award, supporting the development of new power systems [10] - The "Lunar Sampling and Testing Technology" project achieved significant milestones in lunar exploration, contributing to high-end intelligent equipment development in Beijing [10] Group 7: Youth Participation - Over half of the awardees are aged 45 or younger, indicating a vibrant influx of young talent in the field of science and technology [11] - The "Multi-Dimensional Unmanned Aerial Vehicle Ground-Air Collaborative Communication Theory" project received a second-class Natural Science Award, showcasing advancements in disaster monitoring and border inspection [11]